Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.

Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. Gastroenterology. 2018 10; 155(4):1140-1153.

View in: PubMed

subject areas

Amino Acid Oxidoreductases
Antibodies, Monoclonal, Humanized
Biomarkers
Collagen
Disease Progression
Double-Blind Method
Drug Administration Schedule
Enzyme Inhibitors
Europe
Female
Humans
Hypertension, Portal
Injections, Subcutaneous
Liver
Liver Cirrhosis
Male
Middle Aged
Non-alcoholic Fatty Liver Disease
North America
Portal Pressure
Time Factors
Treatment Outcome

authors with profiles

Don C. Rockey